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LETTER TO THE EDITOR
Molecular Diagnostics
in Advanced NSCLC:
Trying to Maximize a
Non-Ideal Situation
To the Editor:
I refer to the Editorial in the May
2007 issue of the JTO, entitled Should
Mutational Analyses of Tumor Samples
Bypass Histopathology?
We are glad that our work has
helped to highlight a clinical manage-
ment issue concerning patients with ad-
vanced non-small cell lung cancer
(NSCLC), namely the lack of sufficient
tissue/cells for mutational analysis. Al-
though efforts to better detect and man-
age early disease continue, it is a fact
that most NSCLC cases are in the ad-
vanced stage at presentation. Therefore,
where improvement of clinical manage-
ment is concerned, patients with ad-
vanced-stage NSCLC pose immediate
and substantial challenges.
By incorporating molecular knowl-
edge into clinical practice, we had hoped
to further the translation of bench find-
ings into patient benefit. This is of par-
ticular relevance to East Asian popula-
tions, in whom the frequency of EGFR
mutations is high. However, health sys-
tems need to contend with economic
feasibility issues, e.g., availability of re-
sources and expertise, impact on hospi-
tal workflows, and assay reliability.
Analyzing tumor cells from patients
with advanced-stage NSCLC is compli-
cated by the low tumor cell numbers in
biopsies and our general reluctance, for
compassionate reasons, to subject pa-
tients to multiple biopsy procedures.
Under such constraints, it would be rea-
sonable to tackle the problem by devel-
oping more sensitive detection methods
and/or by maximizing the diagnostic
procedure. We attempted to determine
the limits of the latter, and in so doing,
address some of the economic feasibility
issues.
We do not “regard split samples
obtained from a single biopsy as equiv-
alent,” precisely because one is histolog-
ically validated and the other is not. In
fact, we stated in the Discussion that it
was “less than ideal” that the low-vol-
ume samples for mutational analysis
were without histological validation. We
were not addressing the question of
“whether histology-bypassed biopsy
samples (could) provide results equiva-
lent to analyses performed on FFPE
samples that were processed primarily
for histologic diagnosis.” We were seek-
ing the maximal yield of mutation infor-
mation from low-volume biopsies using
standard DNA sequencing techniques.
To clarify, we did not take low-
volume biopsies from surgically re-
sected tumors for mutational analysis.
The copious amounts of DNA from sur-
gically resected tissue were used to dem-
onstrate the reliability of our sequencing
technique and validity of the sequence
quality. Now that the feasibility of ob-
taining sequence data from low-volume
samples has been demonstrated, the con-
cordance of sequence data from the low-
volume biopsy (at diagnosis) and surgi-
cal specimen from the same patient may
be examined.
The analysis of the surgically re-
sected tissue showed EGFR mutation
rates (our original Table 4) in the sub-
groups of adenocarcinoma (44%), fe-
male (67%), and non-smoker (73%) as
being consistent with rates previously
reported. The difference in distribution
of patient and tumor characteristics (our
original Table 1) between the surgical
and non-surgical groups was addressed
in the Discussion, where the consent-
giving process may have introduced a
bias, giving rise to different patient pro-
files in which EGFR mutations most
frequently occurred.
The L833V mutations could not
be confirmed. This was because of the
rationing of sample DNA to interrogate
as many different exons as possible, in-
stead of confirming mutations by sepa-
rate independent polymerase chain reac-
tion. This is indeed a limitation of low
tumor cell numbers and reiterates the
need for the development of alterna-
tive genotyping platforms that are
more sensitive and still affordable for
clinical use.
Overall, we did not set out to
prove that histopathology should be by-
passed in mutational analysis.1 In an
ideal situation, we are able to interpret
mutational results in the context of his-
topathologic and cytologic findings. The
nub is in figuring out how to maximize
non-ideal situations. We do not presume
to have found the ideal solution, but we
wanted to share with our colleagues our
attempt at having a stab at the problem.
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